Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening.

A ligand-based virtual screening strategy (a combination of pharmacophore model generation, shape-based scoring, and structure clustering analysis) was developed to discover novel SGLT2 inhibitors. The best pharmacophore model, generated from eight glycoside inhibitors, was utilized to virtually screen three chemical databases that led to the identification of three non-glycoside SGLT2 inhibitors. This is the first report of the generation of a pharmacophore model from glycosides that has then been used to discover novel non-glycosides hits.

[1]  G. Semenza,et al.  Phlorizin as a probe of the small-intestinal Na+,D-glucose cotransporter. A model. , 1982, Biochimica et biophysica acta.

[2]  R. DeFronzo,et al.  Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. , 1987, The Journal of clinical investigation.

[3]  Yvonne C. Martin,et al.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..

[4]  D. Loo,et al.  The sodium/glucose cotransporter (SGLT1). , 1993, Society of General Physiologists series.

[5]  D. Loo,et al.  Biophysical Characteristics of the Pig Kidney Na+/Glucose Cotransporter SGLT2 Reveal a Common Mechanism for SGLT1 and SGLT2* , 1996, The Journal of Biological Chemistry.

[6]  Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats. , 2000, Biological & pharmaceutical bulletin.

[7]  D. Porte,et al.  Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. , 2001, Diabetes/metabolism research and reviews.

[8]  N. Lewis,et al.  Phlorizin: a review , 2005, Diabetes/metabolism research and reviews.

[9]  H. Kawahara,et al.  Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. , 2007, Bioorganic & medicinal chemistry.

[10]  W. Humphreys,et al.  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. , 2008, Journal of medicinal chemistry.

[11]  Yoshikazu Fujimori,et al.  Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models , 2008, Journal of Pharmacology and Experimental Therapeutics.

[12]  O. Marsenic Glucose control by the kidney: an emerging target in diabetes. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  W. Washburn Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents , 2009, Expert opinion on therapeutic patents.

[14]  W. Washburn Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. , 2009, Journal of medicinal chemistry.

[15]  Yoshikazu Fujimori,et al.  Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. , 2009, European journal of pharmacology.

[16]  Simona Distinto,et al.  How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..

[17]  Beat Ernst,et al.  From carbohydrate leads to glycomimetic drugs , 2009, Nature Reviews Drug Discovery.

[18]  H. Morita,et al.  Cyclic Diarylheptanoids as Na+‐Glucose Cotransporter (SGLT) Inhibitors from Acer nikoense. , 2010 .

[19]  H. Morita,et al.  Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. , 2010, Bioorganic & medicinal chemistry.

[20]  R. Henry,et al.  SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.